The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents
Basic Information
Publication number:
EP1753431
WO Application Number:
GB2005001931
Type:
European Patent Granted for NL
Status:
Expired. Art. 36.6 ROW
Publication Title:
Title When Made Available For Viewing:
Reason Lapsed:
Application number:
EP05744858.1
WO Publication Number:
WO2005112934
EPO Publication Language:
English
SPC Number:
First Applicant Residence Country:
Sweden (SE)
Publications:
Dates
Filing date:
18/05/2005
Grant date:
19/08/2009
EP Publication Date:
19/08/2009
WO Publication Date:
Claims Translations Received Date:
Claims Translation B1 Received Date:
Claims Translation B2 Received Date:
Claims Translation B3 Received Date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Published:
Due To Cession Date:
Registration date:
19/08/2009
EP B1 Publication Date:
19/08/2009
EP B2 Publication Date:
EP B3 Publication Date:
Description Translation B1 Received Date:
Description Translation B2 Received Date:
Description Translation B3 Received Date:
Expiration date:
17/05/2025
Lapsed By Expiration Date:
18/05/2025
Revocation Date:
Invalidity Date:
Response To Novelty Search Report Received:
Patent Granting Request:
Lapsed date:
Applicant/holder
From:
25/07/2016
Name:
Genzyme Corporation
Address:
500 Kendall Street, 02142, Cambridge, Massachusetts, United States of America (US)
Historical Applicant/holder
From:
19/08/2009
To:
25/07/2016
Name:
AstraZeneca AB
Address:
Gobal Intellectual Property, S-151 85, Södertälje, Sweden (SE)